Citations 1
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Korecka, Magdalena , Figurski, Michal, Toledo, Jon B. , Blennow, Kaj , Waligórska, Teresa, Brylska, Magdalena, Fields, Leona, Shah, Nirali, Soares, Holly , Dean, Robert A., Vanderstichele, Hugo, Petersen, Ronald C. , Aisen, Paul , Saykin, Andrew J. , Weiner, Michael W. , Trojanowski, John Q. , Shaw, Leslie M. , Initiative, Alzheimer's Disease Neuroimaging, Kang, Ju‐Hee , Zetterberg, Henrik , Initiative, Alzheimer's Disease Neuroimaging, Saykin, Andrew J
Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 772-791
AbstractIntroductionWe describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1–42), t‐tau, and p‐tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids.MethodsReview publications authored or coauthored by ADNI Biomarker core faculty and selected non‐ADNI studies to deepen the understanding and interpretation of CSF Aβ1–42, t‐tau, and p‐tau181 data.ResultsCSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non‐ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies.DiscussionFurther studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease‐modifying therapeutic trials.